The company raised $45.65 million of Series C venture funding led by Axel Springer and Stereo Capital on September 17, 2018, putting the company's pre-money valuation at $180 million. Lattice Biologics, Dawn Capital, Kleiner Perkins, Breyer Capital, Scott Cook, Goodwater Capital, Industrial Investors Group and xfund also participated in the round. The company intends to use the funds to build out its end-to-end platform, and expand its team, bringing on 50 new staff into its San Francisco HQ in the coming months. The company has raised $90m in total funding to date.
Leave a Reply ·
You must be logged in to post a comment.